# Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

> **NCT00434733** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 4400 (estimated)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Pandemic influenza vaccine

## Key facts

- **NCT ID:** NCT00434733
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 4400 (ESTIMATED)
- **Last updated:** 2008-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434733, "Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00434733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*